Simcere Pharmaceutical
Simcere is a Nanjing-based pharmaceutical company whose oncology arm, Simcere Zaiming, is running the phase 3 SIMRISE trial of the oral SERD SIM0270 with everolimus in ER-positive breast cancer and markets the anti-PD-1 antibody enlonstobart in China.
Overview
Simcere Pharmaceutical Group, based in Nanjing and listed in Hong Kong, sells medicines across oncology, neurology and autoimmune disease in China and runs its cancer research through the subsidiary Simcere Zaiming. Its oncology portfolio includes enlonstobart, an anti-PD-1 antibody approved in China for previously treated cervical cancer, the Chinese rights to the myeloprotective drug trilaciclib, and SIM0270, an oral selective oestrogen receptor degrader in the phase 3 SIMRISE trial with everolimus for ER-positive, HER2-negative advanced breast cancer. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Scorecard
All companies- phase 3 +3
- modalities +2
- registry trials +2
Similar pages
not linked directly; found by shared links- CompanyBio-Thera Solutions
Shares Cervical cancer and the tag ctgov-sponsor.
- CompanyForward Pharmaceuticals
Shares HR-positive / HER2-negative breast cancer and the tag ctgov-sponsor.
- CompanyOlema Pharmaceuticals
Shares HR-positive / HER2-negative breast cancer and the tag ctgov-sponsor.
- CompanyMabwell (Shanghai) Bioscience
Shares Cervical cancer and the tag ctgov-sponsor.
- CompanyTreadwell Therapeutics
Shares HR-positive / HER2-negative breast cancer and the tag ctgov-sponsor.
- CompanyOncolytics Biotech
Shares HR-positive / HER2-negative breast cancer and the tag ctgov-sponsor.
- CompanyMBrace Therapeutics
Shares HR-positive / HER2-negative breast cancer and the tag ctgov-sponsor.
- CompanyNeonc Technologies
Shares Cervical cancer and the tag ctgov-sponsor.